Afuresertib plus fulvestrant for pretreated HR-positive, HER2-negative, advanced breast cancer: a phase Ib trial

Journal:

Nature Communications

Published:

2026-02-06

DOI:

10.1038/s41467-026-69225-2

Affiliations:

10

Authors:

12

Go to article

Institutions	Authors	Share
Laekna, China	4.000000	0.33
Cancer Institute and Hospital, CAMS & PUMC, China	2.000000	0.17
Liaoning Cancer Hospital and Institute, China	1.000000	0.08
Sun Yat-sen Memorial Hospital, SYSU, China	1.000000	0.08
The First Hospital of Jilin University, China	1.000000	0.08
Tianjin Medical University Cancer Institute and Hospital, TMU, China	1.000000	0.08
Holden Comprehensive Cancer Center, UI, United States of America (USA)	1.000000	0.08
Piedmont Cancer Institute, United States of America (USA)	1.000000	0.08

Interested in Oncology and Carcinogenesis?